中文
  • About Us
    Corporate Overview Management Team Board of Directors Contact Us
  • Our Focus
    Metabolic Diseases Immune Diseases Exploratory Indications
  • Pipeline
    Pipeline Clinical Trials
  • Partnership
  • Investors
    Financials & Filing
  • News
  • Careers
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Show More
    2014
  • Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

    2023-05-08

  • Ascletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for Acne

    2023-05-02

  • Ascletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech Index

    2023-02-27

  • Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023

    2023-02-21

  • Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B

    2023-02-16

  • Ascletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection

    2023-01-31

  • Ascletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPA

    2023-01-26

  • Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere

    2023-01-17

  • Ascletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19

    2023-01-16

  • Ascletis Believes that the Complaints Made by Viking Therapeutics Have No Merit and will Vigorously Defend Against such Complaints

    2023-01-02

  • «
  •  
  • 1
  • 2
  •  
    • © 2018 Ascletis Pharma Inc.
    • All Rights Reserved

    contact

    • pr@ascletis.com
    • bd@ascletis.com
    • hr@ascletis.com
    • clinicaltrials@ascletis.com

    © 2018 Ascletis Pharma Inc. All Rights Reserved
    浙公网安备 33010802003344号 浙ICP备11050387号-1